pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

107 catalysts · 25 phase 2 completion · 15 phase 1 completion · 13 phase 2 initiation · 13 phase 1 initiation · 10 patent expiry · 5 drug expiry

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 75 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 20 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 8 catalysts2026-11-03: 17 catalysts2026-11-04: 22 catalysts2026-11-05: 36 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
TA: infectious-disease×TA: immunology×TA: dermatology×from 2017-03-10×clear all
type
  • phase 2 completion25
  • phase 1 completion15
  • phase 2 initiation13
  • phase 1 initiation13
  • patent expiry10
drug expiry
5
  • phase 3 initiation5
  • phase 0 trial completion4
  • phase 3 completion4
  • constraining patent expiry europe4
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    50
    ›Apr 28, 2026patent expiry105d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Constraining Patent Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026patent expiry105d agoViiV Healthcare UK Ltd — cabotegravir LA (Constraining Patent Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026drug expiry105d agoGSK plc — cabotegravir sodium (Drug Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026drug expiry105d agoViiV Healthcare UK Ltd — cabotegravir LA (Drug Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026drug expiry105d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Drug Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026pdufa105d agoMerck & Co Inc — (doravirine + islatravir hydrate) (PDUFA)(doravirine + islatravir hydrate)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(doravirine + islatravir hydrate) →source: globaldata
    ›Apr 28, 2026phase 1 completion105d agoGSK plc — bepirovirsen sodium (Phase I Trial Completion)bepirovirsen sodium

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →bepirovirsen sodium →source: globaldata
    ›Apr 28, 2026phase 1 completion105d agoBio-Innova Co Ltd — clarithromycin (Phase I Trial Completion)clarithromycin

    Therapy area: Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genito Urinary System, Infectious Disease, Mouth and Dental Disorders, Respiratory. Indication: Abscess, Acne Vulgaris, Acute Bacterial Sinusitis, Acute Bronchitis, Acute Pharyngitis, Bacterial Pneumonia, Bacterial Respiratory Tract Infections, Bartonella Infections, Bronchitis, Carbuncle, Cellulitis, Chlamydia trachomatis Pneumonia, Chronic Bronchitis, Community Acquired Pneumonia, Community-Acquired

    full page →clarithromycin →source: globaldata
    ›Apr 28, 2026phase 1 initiation105d agoShanghai Argo Pharmaceutical Co Ltd — BW-20805 (Phase I Trial Initiation)BW-20805

    Therapy area: Immunology. Indication: Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

    full page →BW-20805 →source: globaldata
    ›Apr 28, 2026phase 1 initiation105d agoShenzhen MagicRNA Biotech Co Ltd — HN-2302 (Phase I Trial Initiation)HN-2302

    Therapy area: Immunology. Indication: Autoimmune Disorders, Diffuse Cutaneous Systemic Sclerosis, Systemic Sclerosis (Scleroderma)

    full page →HN-2302 →source: globaldata
    ›Apr 28, 2026phase 1 initiation105d agoVirginia Commonwealth University — fluorouracil (Phase I Trial Initiation)Efudex

    Therapy area: Dermatology. Indication: Burns

    full page →Efudex →source: globaldata
    ›Apr 28, 2026phase 2 completion105d agoInonu University — albumin gel- and platelet- rich fibrin (Phase II Trial Completion)albumin gel- and platelet- rich fibrin

    Therapy area: Immunology, Mouth and Dental Disorders. Indication: Inflammation, Periodontal Disease, Periodontitis

    full page →albumin gel- and platelet- rich fibrin →source: globaldata
    ›Apr 28, 2026phase 2 initiation105d agoTianjin Lisheng Pharmaceutical Co Ltd — dexamethasone acetate (Phase II Trial Initiation)dexamethasone acetate

    Therapy area: Immunology, Respiratory. Indication: Allergic Rhinitis, Inflammation, Transplant Rejection

    full page →dexamethasone acetate →source: globaldata
    ›Apr 28, 2026phase 3 completion105d agoGovernment Stanley Medical College Hospital — tenecteplase (Phase III Trial Completion)tenecteplase

    Therapy area: Genito Urinary System, Infectious Disease. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Unspecified Bacterial Infections

    full page →tenecteplase →source: globaldata
    ›Apr 29, 2026phase 1 initiation104d agoOcugen Inc — adenovirus vector (spike protein) vaccine (Phase I Trial Initiation)adenovirus vector (spike protein) vaccine

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)

    full page →adenovirus vector (spike protein) vaccine →source: globaldata
    ›Apr 29, 2026phase 2 completion104d agoSaraswati Dhanwantari Dental College and Hospital Parbhani — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

    Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Periodontitis, Unspecified Infectious Diseases

    full page →(amoxicillin + clavulanic acid) →source: globaldata
    ›Apr 29, 2026phase 2 completion104d agoBangalore Medical College and Research Institute — dinoprostone (Phase II Trial Completion)dinoprostone ER

    Therapy area: Dermatology. Indication: Vitiligo

    full page →dinoprostone ER →source: globaldata
    ›Apr 29, 2026phase 2 initiation104d agoNefro Avillion Clinical Development LLC — siplizumab (Phase II Trial Initiation)siplizumab

    Therapy area: Immunology. Indication: Kidney Transplant Rejection

    full page →siplizumab →source: globaldata
    ›Apr 29, 2026phase 2 initiation104d agoKyowa Kirin Co Ltd — KK-4277 (Phase II Trial Initiation)KK-4277

    Therapy area: Immunology. Indication: Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus

    full page →KK-4277 →source: globaldata
    ›Apr 29, 2026phase 2 initiation104d agoYunpeng Pharmaceutical Co Ltd — norfloxacin (Phase II Trial Initiation)norfloxacin

    Therapy area: Gastrointestinal, Genito Urinary System, Infectious Disease. Indication: Gonorrhea, Intestinal Infection, Salmonella Infections, Typhoid Fever, Urinary Tract Infections

    full page →norfloxacin →source: globaldata
    ›Apr 29, 2026phase 2 initiation104d agoHuahui Health Ltd — HH-006 (Phase II Trial Initiation)HH-006

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →HH-006 →source: globaldata
    ›Apr 30, 2026constraining patent expiry europe103d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

    Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

    full page →telavancin hydrochloride →source: globaldata
    ›Apr 30, 2026patent expiry103d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

    Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

    full page →isavuconazonium sulfate →source: globaldata
    ›Apr 30, 2026phase 0 trial completion103d agoRuijin Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System, Dermatology. Indication: Burns, Pain, Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion103d agoShanghai Jiao Tong University — insulin (Phase 0 Trial Completion)insulin

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →insulin →source: globaldata
    ›Apr 30, 2026phase 0 trial completion103d agoFoundation for the Promotion of Health and Biomedical Research of Valencia — Aquacel Ag + (Phase 0 Trial Completion)Aquacel Ag +

    Therapy area: Dermatology. Indication: Pressure Ulcers

    full page →Aquacel Ag + →source: globaldata
    ›Apr 30, 2026phase 0 trial completion103d agoUniversity of Southern California — methylprednisolone (Phase 0 Trial Completion)MEDROL

    Therapy area: Immunology. Indication: Drug Hypersensitivity Reactions

    full page →MEDROL →source: globaldata
    ›Apr 30, 2026phase 1 completion103d agoDongguan Traditional Chinese Medicine Hospital — undisclosed traditional Chinese medicine (Phase I Trial Completion)undisclosed traditional Chinese medicine

    Therapy area: Immunology, Musculoskeletal Disorders. Indication: Osteoporosis, Rheumatoid Arthritis, Sarcopenia

    full page →undisclosed traditional Chinese medicine →source: globaldata
    ›Apr 30, 2026phase 1 completion103d agoShenzhen Digestive System Disease Clinical Medicine Research Center — tegoprazan (Phase I Trial Completion)tegoprazan

    Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

    full page →tegoprazan →source: globaldata
    ›Apr 30, 2026phase 1 completion103d agoCheng Du Sheng Nuo Biotec Co Ltd — CIGB-814 (Phase I Trial Completion)CIGB-814

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →CIGB-814 →source: globaldata
    ›Apr 30, 2026phase 1 completion103d agoEcolab Inc — (acetaminophen + ibuprofen) (Phase I Trial Completion)(acetaminophen + ibuprofen)

    Therapy area: Central Nervous System, Ear Nose Throat Disorders, Hormonal Disorders, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Ankylosing Spondylitis (Bekhterev's Disease), Dental Pain (Toothache/Tooth Pain), Fever, Fibromyalgia (Fibromyalgia Syndrome), Gouty Arthritis (Gout), Hyperthyroidism, Laryngitis, Low Back Pain, Mixed Pain (Nociceptive Pain/Neuropathic Pain), Musculoskeletal Inflammation, Musculoskeletal Pain, Myalgia (Muscle Pain), Neuropathic Pa

    full page →(acetaminophen + ibuprofen) →source: globaldata
    ›Apr 30, 2026phase 1 completion103d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

    Therapy area: Immunology. Indication: Inflammation

    full page →FT-2109 →source: globaldata
    ›Apr 30, 2026phase 1 completion103d agoMAXVAX Biotechnology Co Ltd — MKK-900 (Phase I Trial Completion)MKK-900

    Therapy area: Infectious Disease. Indication: Respiratory Syncytial Virus (RSV) Infections

    full page →MKK-900 →source: globaldata
    ›Apr 30, 2026phase 1 completion103d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

    Therapy area: Immunology. Indication: Inflammation

    full page →FT-2109 →source: globaldata
    ›Apr 30, 2026phase 1 completion103d agoJohns Hopkins University — ciprofloxacin (Phase I Trial Completion)ciprofloxacin

    Therapy area: Infectious Disease. Indication: Bacillary Dysentery (Shigellosis)

    full page →ciprofloxacin →source: globaldata
    ›Apr 30, 2026phase 1 completion103d agoInsignis Therapeutics Inc — HLK-0006 (Phase I Trial Completion)HLK-0006

    Therapy area: Immunology. Indication: Anaphylaxis, Food Allergy, Peanut Allergy

    full page →HLK-0006 →source: globaldata
    ›Apr 30, 2026phase 1 initiation103d agoGilead Sciences Inc — GS-1701 (Phase I Trial Initiation)GS-1701

    Therapy area: Infectious Disease. Indication: Unspecified Infectious Diseases

    full page →GS-1701 →source: globaldata
    ›Apr 30, 2026phase 1 initiation103d agoJiangsu Vcare PharmaTech Co Ltd — VC-005 (Phase I Trial Initiation)VC-005

    Therapy area: Dermatology. Indication: Atopic Dermatitis (Atopic Eczema)

    full page →VC-005 →source: globaldata
    ›Apr 30, 2026phase 1 initiation103d agoMerck & Co Inc — MK-6050 (Phase I Trial Initiation)MK-6050

    Therapy area: Dermatology. Indication: Hidradenitis Suppurativa

    full page →MK-6050 →source: globaldata
    ›Apr 30, 2026phase 1 initiation103d agoNanjing IASO Biotherapeutics Co Ltd — IASO-782 (Phase I Trial Initiation)IASO-782

    Therapy area: Immunology. Indication: Systemic Lupus Erythematosus

    full page →IASO-782 →source: globaldata
    ›Apr 30, 2026phase 1 initiation103d agoThe National Institute of Allergy and Infectious Diseases — dasatinib (Phase I Trial Initiation)DASATINIB

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →DASATINIB →source: globaldata
    ›Apr 30, 2026phase 1 2 completion103d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

    Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

    full page →verteporfin →source: globaldata
    ›Apr 30, 2026phase 1 2 completion103d agoCentre International de Développement Pharmaceutique — afamelanotide (Phase I/II Trial Completion)afamelanotide

    Therapy area: Dermatology. Indication: Vitiligo

    full page →afamelanotide →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoUsynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)UA-021

    Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

    full page →UA-021 →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoVaidya Yagya Dutt Sharma Ayurvedic P. G. Mahavidhyalaya — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

    Therapy area: Dermatology. Indication: Burns

    full page →ayurvedic medicine →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →telitacicept →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoQinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

    Therapy area: Gastrointestinal, Infectious Disease. Indication: Gastritis, Helicobacter pylori Infections

    full page →amoxicillin →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoGuy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)autologous regulatory T cells

    Therapy area: Genito Urinary System, Immunology. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Kidney Transplant Rejection

    full page →autologous regulatory T cells →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

    Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

    full page →tulisokibart →source: globaldata
    ›Apr 30, 2026phase 2 completion103d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

    Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

    full page →ozonated oil →source: globaldata
    ← prev
    page 2 of 3
    next →
    $ECL284.40-0.27%
    $CPIX7.7900-0.13%
    $OCGN1.2800-2.29%
    $MRK130.92+1.82%
    $GSK52.16-1.51%
    $MRK130.92+1.82%
    $GILD133.06-0.11%
    $GSK52.16-1.51%
    $MRK130.92+1.82%